Invasive aspergillosis in patients with acute leukemia: Update on morbidity and mortality - SEIFEM-C report [6]

Clinical Infectious Diseases

Volumn 44, Issue 11, 2007, Pages 1524-1525

  Pagano, Livio ^a   Caira, Morena ^a   Picardi, Marco ^b   Candoni, Anna ^c   Melillo, Lorella ^d   Fianchi, Luana ^a   Offidani, Massimo ^e   Nosari, Annamaria ^f  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

^d Ospedale S Giovanni Rotondo   (Italy)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ACUTE LEUKEMIA; ANTIBIOTIC PROPHYLAXIS; ASPERGILLOSIS; ASPERGILLUS; CANCER MORTALITY; DEATH; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DRUG EFFICACY; EVALUATION; GALACTOMANNAN TEST; HUMAN; INCIDENCE; INVASIVE ASPERGILLOSIS; LETTER; MORBIDITY; PRIORITY JOURNAL; RELIABILITY;

ASPERGILLOSIS; HUMANS; INCIDENCE; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; MORBIDITY; MULTICENTER STUDIES;

EID: 34249060645     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/517849     Document Type: Letter

References (11)

1. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. 13 Aspergillus Study Group. Medicine 2000; 79:250-60.
2. Pagano L, Girmenia C, Mele L, et al. Infections caused by filamentous fungi in patients with hematological malignancies: a report of 391 cases by GIMEMA infection. Haematologica 2001; 86:862-70.
3. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91:1068-75.
4. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41:1242-50.
5. Donnelly JR Consensus definitions for invasive fungal disease: strengths, limitations, and revisions. Med Mycol 2006; 44(Suppl):285-8.
6. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
7. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39:1563-71.
8. Aliff TB, Maslak PG, Jurcic J, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97:1025-32.
9. Candoni A, Mestroni R, Damiani D. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol 2005; 75:227-33.
10. Comely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis 2007; 44:1289-97.
11. Comely O, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. New Engl J Med 2007; 356:348-59.